Search Results - "Volterra, F."

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer by Mayer, E.L., Dhakil, S., Patel, T., Sundaram, S., Fabian, C., Kozloff, M., Qamar, R., Volterra, F., Parmar, H., Samant, M., Burstein, H.J.

“…The vascular endothelial growth factor (VEGF) pathway can be targeted through VEGF neutralization or VEGF receptor (VEGFR) blockade using tyrosine kinase…”
Get full text

898TiP - The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza) by Vogelzang, N.J., Gabrail, N., Malik, Z., Volterra, F., Nordquist, L.T., Levin, R., Zhang, P., Zhou, K.

“…Prostate cancer is the most common malignant tumor in men and is the second leading cause of cancer-related deaths in men. Recently there are several 2nd…”
Get full text

The extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza) by Vogelzang, N.J., Gabrail, N., Malik, Z., Volterra, F., Nordquist, L.T., Levin, R., Zhang, P., Zhou, K.

Get full text

898TiPThe extended/phase II study of safety and tolerability of proxalutamide (GT0918) in subjects with metastatic castrate resistant prostate cancer (mCRPC) who failed either abiraterone (Abi) or enzalutamide (Enza) by Vogelzang, N J, Gabrail, N, Malik, Z, Volterra, F, Nordquist, L T, Levin, R, Zhang, P, Zhou, K

“…Abstract Background Prostate cancer is the most common malignant tumor in men and is the second leading cause of cancer-related deaths in men. Recently there…”
Get full text

Phase I trial of CPI-613, a lipoic acid analog, and gemcitabine in patients with advanced solid tumors by Retter, A. S., Shorr, R., Rodriguez, R., Hoffman, K., Volterra, F., Hoffman, A. D., Huppert, N., Lee, K.

“…Abstract only…”
Get full text

Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T) by Sylvester, L., Laufman, L., Jabboury, K., Saleh, M., Tkaczuk, K., Volterra, F., Arnott, J., Hannah, A., Sidor, C., Miller, K.

“…Abstract only 11508 Background: MKC-1 (previously Ro 31–7453) is a novel cell cycle inhibitor with significant in vitro and in vivo activity against a wide…”
Get full text

A phase I safety and dose escalation trial of docetaxel combined with GEM®231, a second generation antisense oligonucleotide targeting protein kinase A R1α in patients with advanced solid cancers by Goel, Sanjay, Desai, Kavita, Macapinlac, Manuel, Wadler, Scott, Goldberg, Gary, Fields, Abbie, Einstein, Mark, Volterra, Fabio, Wong, Benny, Martin, Russell, Mani, Sridhar

Get full text

A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer by GOEL, Sanjay, WADLER, Scott, HOFFMAN, Anthony, VOLTERRA, Fabio, BAKER, Cheryl, NAZARIO, Elliot, IVY, Percy, SILVERMAN, Alyson, MANI, Sridhar

“…The analog, rebeccamycin tartrate salt (NSC 655649, Cancer Therapy Evaluation Program, National Cancer Institute) has broad preclinical anti-neoplastic…”
Get full text

Intracaval and Intracardiac Metastatic Nonseminomatous Germ Cell Tumor: A Rare Cause of Hemolytic Anemia and Thrombocytopenia by Fishman, Ari D., Hoffman, Anthony, Volterra, Fabio, Frymus, Michael, Gentilluci, Marco

“…Intracaval and intracardiac nonseminomatous germ cell tumor metastases although rare have been previously reported in the literature. Most cases arise as a…”
Get full text